Wyeth: Pipeline, Products, Performance, Potential

Date: March 22, 2008
Pages: 152
Price:
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W0EA03185C7EN
Leaflet:

Download PDF Leaflet

Wyeth: Pipeline, Products, Performance, Potential
Wyeth is one of the world’s largest research-based pharmaceutical and healthcare products companies and is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, biotechnology products, vaccines, non-prescription medicines and animal health products. Wyeth currently operates in over 145 countries worldwide.

Fiscal 2007 was a strong year for Wyeth, with the company achieving record levels of sales and income. In terms of pharmaceuticals sales, Wyeth maintained its place in the top ten research-based pharmaceutical companies worldwide. This success was based on strong growth of its biotechnology products Enbrel and Prevnar, the launch of Torisel and Lybrel, and the company's continued expansion into China, the Middle East and Latin America. Furthermore, Wyeth reported successful cost-management efforts through the efficient implementation of its "Project Springboard" scheme.

Wyeth’s growth is based on a strong foundation of products, which includes Effexor, Protonix, Enbrel, Prevnar, Zosyn, and the Premarin franchise. Productivity, coupled with significant investment in facilities (for example, Wyeth’s US$2 billion biotech manufacturing site in Grange Castle, Ireland) allowed the company to achieve record levels of production for its lead vaccine, Prevnar, and accommodation of the increasing demand for Enbrel, which is fast becoming one of the world’s leading rheumatoid arthritis treatments.

However, sustained growth is threatened by the loss of patent protection for several products including Effexor (Wyeth’s top-seller), Prevnar and Zosyn. Wyeth has assembled a strong pipeline, which may yield compounds to follow in the footsteps of these leading products. Desvenlafaxine and the 13-valent pneumococcal vaccine have the potential to succeed Effexor and Prevnar respectively, whilst the recently-launched Tygacil is anticipated to provide a boost to the Anti-infective therapeutic area, whose sales were set to suffer with the loss of Zosyn’s market protection.
EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting
Neuroscience
  Effexor (venlafaxine)
  Pristiq (desvenlafaxine succinate)
Gastroenterology
  Protonix (pantoprazole)
  Relistor (methylnaltrexone)
Vaccines
  Prevnar/Prevenar (7-valent glycoconjugate)
Musculoskeletal
  Enbrel (etanercept)
  rhBMP-2/Inductos (dibotermin alpha)
Women's Healthcare/Contraception
  Lybrel/Anya (levonorgestral+ethinyloestradiol)
  Oral contraceptives
  Premarin (conjugated oestrogens)
Anti-Infectives
  Tazocin/Zosyn (tazobactam)
  Tygacil (tigecycline)
Haemophilia
  BeneFIX (recombinant Factor IX)
  ReFacto (recombinant Factor VIII)
Immunology
  Rapamune (sirolimus)
Oncology
  Torisel (temsirolimus)

OPERATIONAL DATA

A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries and joint ventures
Skip to top


UCB: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 82 pages
Merck & Co: Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2009 · 186 pages
Allergan: Pipeline, Products, Performance, Potential US$ 1,040.00 Apr, 2009 · 80 pages
Biogen Idec: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 86 pages

Ask Your Question

Wyeth: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: